| Not Yet Recruiting | Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress NCT06999109 | Duke University | N/A |
| Not Yet Recruiting | Study of NM8074 in Patients with Dermatomyositis (DM) NCT06887738 | NovelMed Therapeutics | Phase 2 |
| Not Yet Recruiting | Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study NCT07486869 | University of Miami | Phase 2 |
| Not Yet Recruiting | Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory NCT07122648 | Paean Biotechnology Inc. | Phase 2 |
| Recruiting | A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 NCT07403188 | Kyverna Therapeutics | — |
| Withdrawn | Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis NCT07012057 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Recruiting | RCT of Tocilizumab for Anti-MDA5+DM NCT07377058 | Peking Union Medical College Hospital | N/A |
| Recruiting | Panniculitis in Dermatomyositis NCT07345949 | University Hospital, Strasbourg, France | — |
| Recruiting | MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) NCT07374107 | Myositis International Health & Research Collaborative Alliance Foundation | — |
| Recruiting | Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis NCT06857240 | The Cleveland Clinic | Phase 2 |
| Recruiting | Intralesional Injection of STS in Treatment of Calcinosis NCT06672822 | Robyn T. Domsic, MD, MPH | Phase 2 |
| Recruiting | A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathie NCT06698796 | Pfizer | Phase 3 |
| Recruiting | Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases NCT06732674 | Oslo University Hospital | N/A |
| Recruiting | Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases NCT06685042 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 1 / Phase 2 |
| Recruiting | Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment o NCT06686524 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Not Yet Recruiting | Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic NCT06599411 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predomin NCT06433999 | Priovant Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis NCT06284954 | argenx | Phase 2 |
| Recruiting | Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis NCT06298019 | Stanford University | Phase 1 |
| Enrolling By Invitation | 3T Therapy in the Treatment of MDA5-positive Dermatomyositis NCT06438679 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 |
| Recruiting | Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings NCT07037472 | Peking Union Medical College Hospital | N/A |
| Recruiting | RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Id NCT06154252 | Cabaletta Bio | Phase 2 / Phase 3 |
| Recruiting | Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis NCT06462768 | CHU de Reims | — |
| Recruiting | Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis NCT06004817 | Central Hospital, Nancy, France | — |
| Enrolling By Invitation | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults Wi NCT05979441 | argenx | Phase 3 |
| Unknown | Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopath NCT05833711 | Immunoforge Co. Ltd. | Phase 2 |
| Recruiting | Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease NCT06056921 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease NCT06347718 | Miltenyi Biomedicine GmbH | Phase 1 / Phase 2 |
| Unknown | Study on Lymphocyte Subsets of Peripheral Blood in Patients With Nonmyopathic Dermatomyositis Complicated With NCT06149039 | Yanfeng Hou | — |
| Active Not Recruiting | A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomy NCT05695950 | Galapagos NV | Phase 2 |
| Terminated | Study of M5049 in DM and PM Participants (NEPTUNIA) NCT05650567 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Unknown | Plexin D1 as a Potential Biomarker inPM/DM NCT05637931 | Assiut University | — |
| Enrolling By Invitation | Interleukin-2 on Active Dermatomyositis NCT05495321 | Peking University People's Hospital | Phase 3 |
| Active Not Recruiting | A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis NCT05437263 | Priovant Therapeutics, Inc. | Phase 3 |
| Active Not Recruiting | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiop NCT05523167 | argenx | Phase 2 / Phase 3 |
| Recruiting | Baricitinib in Patients With Relapsing or naïve Dermatomyositis NCT04972760 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Unknown | Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis NCT05488327 | Jiangxi Provincial People's Hopital | N/A |
| Withdrawn | Baricitinib for Cutaneous Dermatomyositis NCT05361109 | University of Washington | Phase 2 |
| Unknown | Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases NCT05239702 | Zhejiang University | EARLY_Phase 1 |
| Completed | An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study NCT05192200 | Pfizer | Phase 2 |
| Completed | Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis NCT04976140 | Paean Biotechnology Inc. | Phase 1 / Phase 2 |
| Completed | Evaluation of Tp-e Interval and Tp-e/QT Ratio in Dermatomyositis and Analysis of Their Relationship With Infla NCT06002750 | The Third People's Hospital of Hangzhou | — |
| Terminated | Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis NCT04999020 | Alexion Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Completed | Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) NCT04723303 | University of Florida | EARLY_Phase 1 |
| Active Not Recruiting | Add-on Intravenous Immunoglobulins in Early Myositis NCT05832034 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 / Phase 3 |
| Completed | Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties NCT05027152 | Federal University of Espirito Santo | N/A |
| Completed | High-intensity Strength Training in Myositis NCT04486261 | Rigshospitalet, Denmark | N/A |
| Recruiting | Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLES NCT07265999 | Centre Hospitalier Universitaire de la Guadeloupe | — |
| Unknown | An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis NCT04946669 | The First Affiliated Hospital with Nanjing Medical University | EARLY_Phase 1 |
| Completed | Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. NCT04628936 | Kezar Life Sciences, Inc. | Phase 2 |
| Recruiting | Rheumatology Patient Registry and Biorepository NCT04402086 | Yale University | — |
| Unknown | Clinical Research on Advanced Warning Factors Of Respiratory Injury in Dermatomyositis NCT04747652 | The First Affiliated Hospital with Nanjing Medical University | — |
| Completed | A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyos NCT04033926 | Kezar Life Sciences, Inc. | Phase 2 |
| Recruiting | Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study NCT03582800 | University Hospital, Limoges | Phase 2 |
| Terminated | Exercise Capacity of Patients with Dermatomyosis NCT03293615 | University Hospital, Strasbourg, France | N/A |
| Terminated | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) NCT04044690 | CSL Behring | Phase 3 |
| Withdrawn | Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders NCT02418273 | Indiana University | Phase 1 / Phase 2 |
| Terminated | A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Re NCT03981744 | Janssen Pharmaceutical K.K. | Phase 3 |
| Recruiting | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorde NCT03816345 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Biomarkers of Cancer-Associated Myositis NCT06808672 | Azienda USL Reggio Emilia - IRCCS | — |
| Completed | Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis NCT03813160 | Corbus Pharmaceuticals Inc. | Phase 3 |
| Completed | A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythemat NCT03817424 | Amgen | Phase 1 |
| Terminated | Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis NCT03686969 | Octapharma | Phase 3 |
| Completed | A Study In Adults With Moderate To Severe Dermatomyositis NCT03181893 | Pfizer | Phase 2 |
| Completed | Predictor of Clinical Response to Acthar in Myositis NCT03414086 | University of Pittsburgh | — |
| Completed | Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis NCT03267277 | National Institute of Environmental Health Sciences (NIEHS) | Phase 2 / Phase 3 |
| Unknown | Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis NCT03324152 | Karolinska University Hospital | N/A |
| Unknown | Basiliximab Treating Interstitial Pneumonia of CADM NCT03192657 | RenJi Hospital | Phase 2 |
| Completed | Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standa NCT02971683 | Bristol-Myers Squibb | Phase 3 |
| Withdrawn | Study of IFN-K in Dermatomyositis NCT02980198 | Neovacs | Phase 2 |
| Completed | Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory NCT02728752 | Octapharma | Phase 3 |
| Completed | Study of Tofacitinib in Refractory Dermatomyositis NCT03002649 | Johns Hopkins University | Phase 1 |
| Completed | Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud NCT03027674 | Pontificia Universidad Catolica de Chile | EARLY_Phase 1 |
| Completed | Abatacept in Juvenile Dermatomyositis NCT02594735 | George Washington University | Phase 4 |
| Completed | Trial of IMO-8400 in Adult Patients With Dermatomyositis NCT02612857 | Idera Pharmaceuticals, Inc. | Phase 2 |
| Completed | Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyos NCT02245841 | The Cleveland Clinic | Phase 4 |
| Terminated | Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis NCT02466243 | Corbus Pharmaceuticals Inc. | Phase 2 |
| Unknown | PatientSpot Formerly Known as ArthritisPower NCT03840928 | Global Healthy Living Foundation | — |
| Terminated | Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study NCT02271165 | Thomas Jefferson University | EARLY_Phase 1 |
| Completed | Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis NCT02043548 | Chester Oddis | Phase 2 |
| Completed | Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy NCT02880527 | University Hospital, Rouen | — |
| Completed | Environmental Risk Factors for Myositis in Military Personnel NCT01734369 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | Acthar in Treatment of Refractory Dermatomyositis and Polymyositis NCT01906372 | Rohit Aggarwal, MD | Phase 2 |
| Unknown | Dermatomyositis and Polymyositis Registry NCT01637064 | Phoenix Neurological Associates, LTD | — |
| Recruiting | Environmental Risk Factors for the Anti-synthetase Syndrome NCT01276470 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | Abatacept Treatment in Polymyositis and Dermatomyositis NCT01315938 | Karolinska Institutet | Phase 2 |
| Completed | Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies NCT01432613 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis NCT01813617 | Karolinska University Hospital | — |
| Terminated | Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis NCT01148810 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With De NCT01140503 | Stanford University | N/A |
| Recruiting | Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CD NCT02945345 | University of Pennsylvania | — |
| Completed | Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM NCT00651040 | Institute of Rheumatology, Prague | Phase 3 |
| Completed | Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis NCT01415219 | University Hospital, Lille | Phase 2 |
| Completed | Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus NCT00504348 | Tokyo Medical and Dental University | Phase 2 / Phase 3 |
| Completed | Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/D NCT00335985 | Japan Blood Products Organization | Phase 3 |
| Completed | A Pilot Study of Etanercept in Dermatomyositis NCT00112385 | Brigham and Women's Hospital | Phase 1 |
| Completed | Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) NCT00106184 | University of Pittsburgh | Phase 2 |
| Completed | Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases NCT00341679 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies NCT00213629 | University Hospital, Rouen | N/A |
| Completed | Anakinra in Myositis NCT01165008 | Karolinska Institutet | Phase 2 / Phase 3 |
| Terminated | Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis NCT00035958 | Children's Hospital Medical Center, Cincinnati | Phase 2 / Phase 3 |
| Completed | Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis NCT00033891 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Completed | Hand Function in Patients With Poly- or Dermatomyositis NCT00866125 | Karolinska Institutet | — |
| Completed | Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autol NCT00010335 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis NCT00005571 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Completed | Absorption of Corticosteroids in Children With Juvenile Dermatomyositis NCT00004357 | Northwestern University | Phase 2 |
| Recruiting | Adult and Juvenile Myositis NCT00017914 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | Methimazole to Treat Polymyositis and Dermatomyositis NCT00001421 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity NCT03941184 | Mayo Clinic | — |
| Completed | Genetic and Family Studies of Inherited Muscle Diseases NCT00001331 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | — |
| Completed | Study and Treatment of Inflammatory Muscle Diseases NCT00001265 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | — |
| Completed | Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies NCT00001261 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |